Also known as: Samsung Bioepis
Samsung Bioepis is a biopharmaceutical company focused on biosimilars and novel biologics intended to improve affordability and access. Founded in 2012 and headquartered in Incheon, Korea, it has developed and commercialized products across major therapeutic areas and global markets.
A new recruit from DLA Piper will head up a firm's litigation team. The recruit previously worked on Pfizer v Samsung Bioepis and other cases. The appointment follows prosecutor Chris Vindurampulle, who joined in October last year.
Samsung Bioepis plans to start a global Phase 1 trial of SBE303, its first independently developed new drug candidate targeting Nectin-4. Preclinical data showed tolerability up to 40 mg/kg in monkeys.
Samsung Bioepis reached settlement agreements with Regeneron and Bayer for its aflibercept biosimilar OPUVIZ, enabling U.S. launch in January 2027 and staged international rollout beginning early 2026.
Dr. Reddy's Laboratories secures FDA acceptance for DRL-AB, the first abatacept biosimilar application in the U.S., targeting a market worth $3.7 billion annually and positioning the company for first-mover advantage.
Samsung Bioepis and Regeneron reached a settlement allowing U.S. launch of Opuviz, an aflibercept biosimilar, in January 2027. The agreement resolves a patent dispute that began in late 2023.
